Stepping down at the company’s annual meeting next month are Gabriel Urwitz, Peter Sjöstrand, Allen Han, and Dr Yuelong Huang.
Thanking them, chairman Dr Mike Sinclair said: “As valued board members, they have helped Advanced Oncotherapy to progress to a leading position as a technology disruptor in proton therapy, and we wish them all the best in their future endeavours.”
The slimmed-down board will consist of three executive members and five non-executive directors.
AVO is a developer of next-generation proton therapy systems for cancer treatment.
The technology is based on work by ADAM, which AVO bought in 2013 from CERN – the European particle physics lab that built the Hadron collider.
The major plus point of proton therapy is that it can pinpoint tumours more precisely, which means less damage to surrounding healthy tissues.
Proton therapy facilities have traditionally been pricey and large, requiring a space the size of a football pitch to run.
But AVO thinks it has solved that problem, and LIGHT is being built to fit in the basement of a townhouse in Harley Street, central London.
Its modular design, lighter weight and better proton efficiency also help to keep costs down, which should open proton therapy up to many more patients.
The first patient is expected to be treated at Harley Street next year.